The main beneficiary of Roche’s discontinuation of an investigational spinal muscular atrophy drug is Scholar Rock, which was hobbled by manufacturing concerns at a Novo Nordisk facility last year but ...

A questionnaire circulated by the commerce ministry’s supply chain division to key stakeholders has asked firms to disclose granular data on import dependence, covering specific items, source ...

Moby Strategic Performance and Portfolio Evolution. Revenue more than doubled in 2025 following the successful launch of ...

FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in ...

As the pandemic tailwind fades, both Pfizer (PFE) and Moderna (MRNA) have posted financial results that have disappointed investors. Yet, facing the same headwinds, these two companies ...

On March 19, Barclays raised its price recommendation on Johnson & Johnson (NYSE:JNJ) to $234 from $217. It kept an Equal ...

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and ...

Eli Lilly (LLY 0.11%) and Vertex Pharmaceuticals (VRTX +0.45%) have several things in common. Both are among the more prominent drugmakers in the world, and both have delivered ma ...

Egis’ growth capital supports AMAG’s commitment to serving high-security environments and investing in advanced ...

Is BCRX a good stock to buy? We came across a bullish thesis on BioCryst Pharmaceuticals, Inc. on TradersPro’s Substack. In ...

ZHONGSHAN CITY, GUANGDONG PROVINCE, CHINA, March 19, 2026 /EINPresswire.com/ -- In industries where a single particle ...

Seasoned life science investor, executive and board leader to support next phase of growth as BOOST Pharma advances BT-101, a promising and potentially disease-modifying therapy for osteogenesis ...